Cara Therapeutics Management
Management criteria checks 2/4
Cara Therapeutics' CEO is Chris Posner, appointed in Nov 2021, has a tenure of 3.08 years. total yearly compensation is $2.92M, comprised of 24.9% salary and 75.1% bonuses, including company stock and options. directly owns 0.22% of the company’s shares, worth $50.83K. The average tenure of the management team and the board of directors is 3.1 years and 5.4 years respectively.
Key information
Chris Posner
Chief executive officer
US$2.9m
Total compensation
CEO salary percentage | 24.9% |
CEO tenure | 3.1yrs |
CEO ownership | 0.2% |
Management average tenure | 3.1yrs |
Board average tenure | 5.4yrs |
Recent management updates
Recent updates
Cara Therapeutics, Inc.'s (NASDAQ:CARA) Share Price Is Matching Sentiment Around Its Revenues
Nov 01Cara Therapeutics, Inc.'s (NASDAQ:CARA) Price Is Right But Growth Is Lacking After Shares Rocket 34%
Jul 18We Think Cara Therapeutics, Inc.'s (NASDAQ:CARA) CEO Compensation Package Needs To Be Put Under A Microscope
May 29Why Investors Shouldn't Be Surprised By Cara Therapeutics, Inc.'s (NASDAQ:CARA) Low P/S
May 25We're A Little Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate
Feb 16The Market Doesn't Like What It Sees From Cara Therapeutics, Inc.'s (NASDAQ:CARA) Revenues Yet As Shares Tumble 43%
Dec 19News Flash: Analysts Just Made A Notable Upgrade To Their Cara Therapeutics, Inc. (NASDAQ:CARA) Forecasts
Nov 04Can Cara Therapeutics (NASDAQ:CARA) Afford To Invest In Growth?
Oct 25Is Cara Therapeutics (NASDAQ:CARA) In A Good Position To Deliver On Growth Plans?
Jul 20Take Care Before Jumping Onto Cara Therapeutics, Inc. (NASDAQ:CARA) Even Though It's 30% Cheaper
Jun 04News Flash: 8 Analysts Think Cara Therapeutics, Inc. (NASDAQ:CARA) Earnings Are Under Threat
Mar 11Cara Therapeutics, Inc. (NASDAQ:CARA) Analysts Just Slashed Next Year's Estimates
Feb 15We Think Cara Therapeutics (NASDAQ:CARA) Can Afford To Drive Business Growth
Feb 06We're Interested To See How Cara Therapeutics (NASDAQ:CARA) Uses Its Cash Hoard To Grow
Oct 18Cara's partner files for Japanese approval of Korsuva to treat itch in hemodialysis patients
Sep 28Cara Therapeutics hires new finance chief
Sep 12Cara Therapeutics: All Eyes On Korsuva Launch Metrics
Sep 01Cara, Vifor's Kapruvia gets approval in Switzerland to treat itch in hemodialysis patients
Aug 19Cara Therapeutics GAAP EPS of -$0.08 beats by $0.18, revenue of $23M beats by $1.97M
Aug 08Calls A Much Safer Way To Buy Cara Therapeutics
Jun 24We're Not Very Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate
Jun 15Brokers Are Upgrading Their Views On Cara Therapeutics, Inc. (NASDAQ:CARA) With These New Forecasts
May 12Taking A (Speculative) Position In Cara Therapeutics
Mar 21Companies Like Cara Therapeutics (NASDAQ:CARA) Are In A Position To Invest In Growth
Mar 09Cara Therapeutics: De-Risked And Extremely Attractive
Dec 25Checking Back In On Cara Therapeutics
Nov 01CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Sep 30 2024 | n/a | n/a | -US$96m |
Jun 30 2024 | n/a | n/a | -US$111m |
Mar 31 2024 | n/a | n/a | -US$123m |
Dec 31 2023 | US$3m | US$728k | -US$119m |
Sep 30 2023 | n/a | n/a | -US$117m |
Jun 30 2023 | n/a | n/a | -US$112m |
Mar 31 2023 | n/a | n/a | -US$84m |
Dec 31 2022 | US$3m | US$700k | -US$85m |
Sep 30 2022 | n/a | n/a | -US$89m |
Jun 30 2022 | n/a | n/a | -US$66m |
Mar 31 2022 | n/a | n/a | -US$93m |
Dec 31 2021 | US$10m | US$116k | -US$88m |
Sep 30 2021 | n/a | n/a | US$24m |
Jun 30 2021 | n/a | n/a | US$8m |
Mar 31 2021 | n/a | n/a | US$14m |
Dec 31 2020 | US$280k | n/a | US$8m |
Sep 30 2020 | n/a | n/a | -US$99m |
Jun 30 2020 | n/a | n/a | -US$115m |
Mar 31 2020 | n/a | n/a | -US$113m |
Dec 31 2019 | US$302k | n/a | -US$106m |
Sep 30 2019 | n/a | n/a | -US$98m |
Jun 30 2019 | n/a | n/a | -US$85m |
Mar 31 2019 | n/a | n/a | -US$79m |
Dec 31 2018 | US$494k | n/a | -US$74m |
Compensation vs Market: Chris's total compensation ($USD2.92M) is above average for companies of similar size in the US market ($USD653.16K).
Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.
CEO
Chris Posner (54 yo)
3.1yrs
Tenure
US$2,922,469
Compensation
Mr. Christopher A. Posner also known as Chris, served as Independent Director of Zevra Therapeutics, Inc. (formerly known as KemPharm, Inc.), since November 2022. He serves as President and Chief Executive...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 3.1yrs | US$2.92m | 0.22% $ 50.8k | |
Chief Financial Officer | 2.3yrs | US$1.24m | 0.015% $ 3.4k | |
Co-Founder & Senior Advisor | 3.1yrs | US$10.20m | no data | |
Chief Compliance Officer | 8.1yrs | US$1.59m | 0.15% $ 34.5k | |
Manager of Investor Relations | no data | no data | no data |
3.1yrs
Average Tenure
57.5yo
Average Age
Experienced Management: CARA's management team is considered experienced (3.1 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 6.3yrs | US$2.92m | 0.22% $ 50.8k | |
Independent Chairman & Lead Independent Director | 14.4yrs | US$519.99k | 0.20% $ 46.4k | |
Member of the Scientific Advisory Board | no data | no data | no data | |
Member of the Scientific Advisory Board | no data | no data | no data | |
Member of the Scientific Advisory Board | no data | no data | no data | |
Member of the Scientific Advisory Board | no data | no data | no data | |
Independent Director | 10.4yrs | US$272.49k | 0.087% $ 20.2k | |
Independent Director | 1.3yrs | US$376.01k | 0% $ 0 | |
Independent Director | 4.5yrs | US$262.49k | 0.094% $ 21.7k | |
Independent Director | 2.1yrs | US$254.99k | 0.059% $ 13.7k |
5.4yrs
Average Tenure
61.5yo
Average Age
Experienced Board: CARA's board of directors are considered experienced (5.4 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/22 10:49 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cara Therapeutics, Inc. is covered by 15 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Jason Matthew Gerberry | BofA Global Research |
Corey Davis | Canaccord Genuity |
Charles Duncan | Cantor Fitzgerald & Co. |